Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date

Rhea-AI Summary

Target ALS has partnered with PacBio (PACB) to launch the world's largest whole genome sequencing initiative for ALS research, analyzing over 6,000 genomes using PacBio's HiFi long-read sequencing technology. The project aims to identify structural variants and genetic features that may cause ALS, a neurodegenerative disease affecting nerve cells. PacBio's HiFi technology captures DNA fragments of 1,000-20,000 base pairs, significantly longer than traditional short-read methods (50-300 base pairs), enabling better detection of complex genomic regions. The data will be freely shared through the Target ALS Data Engine, allowing researchers worldwide to access comprehensive genetic information. This initiative is particularly significant as 90% of ALS patients don't know their disease's cause, and the project could lead to breakthrough discoveries in ALS research, diagnostics, and treatment.

Positive

• Partnership with Target ALS for largest global ALS genomic study positions PacBio as a leader in neurodegenerative disease research
• HiFi technology's superior capabilities in detecting complex genetic variants demonstrates competitive advantage over traditional sequencing methods
• Free global access to sequencing data through Target ALS Data Engine could accelerate adoption of PacBio's technology
• Project's scale (6,000 genomes) represents significant commercial opportunity and validation of PacBio's technology

Negative

• None.

Insights

Biotechnology Research Specialist

PacBio's HiFi sequencing technology selected for major ALS research initiative, strengthening its position in the long-read sequencing market.

Target ALS's selection of PacBio for the largest global ALS genomic study represents a significant scientific endorsement of PacBio's HiFi long-read sequencing technology. This 6,000-genome initiative highlights a critical technical advantage of PacBio's platform: the ability to detect structural variants, repeat expansions, and complex genetic elements that are typically missed by conventional short-read sequencing methods.

The technical differentiation is substantial - while short-read technologies capture only 50-300 base pairs, PacBio's HiFi technology sequences fragments ranging from 1,000 to 20,000 base pairs. This capability is particularly valuable for neurodegenerative disease research like ALS, where complex genetic factors in non-coding regions may play critical roles.

Beyond the immediate project, this partnership strengthens PacBio's position in the competitive genomics market. By demonstrating real-world utility in high-profile research addressing a devastating disease with limited treatment options, PacBio enhances its scientific credibility. The data will be freely available through Target ALS's Data Engine, creating a showcase for PacBio's technology that could drive adoption across research institutions globally.

This project also aligns with the broader industry trend toward more comprehensive genomic analysis in complex diseases. As multi-omic approaches become standard in disease research, PacBio's ability to provide not just genomic data but also transcript isoform information and methylation profiles from the same samples positions it advantageously in the evolving precision medicine landscape.

Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide

NEW YORK and MENLO PARK, Calif., June 2, 2025 /PRNewswire/ -- Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long read sequencing platforms, to launch the largest global whole genome sequencing initiative for ALS to date. By applying PacBio's HiFi sequencing to more than 6,000 genomes from people with ALS and healthy controls, the project aims to detect structural variants, repeat expansions, and other hard-to-detect genetic features that may underlie the disease. As part of the ALS Global Research Initiative (AGRI), all data will be openly shared via the Target ALS Data Engine, removing barriers to access and enabling researchers around the world to uncover disease mechanisms and explore new pathways to treatment.

The Importance of Long-Read Sequencing for ALS

ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, gradually robbing individuals of muscle control and mobility. While genetic factors are known to play a role in some forms of ALS, much about the disease's origins and progression remains unknown. PacBio HiFi sequencing offers the resolution needed to detect these elements with greater confidence, particularly in non-coding regions of the genome, where regulatory disruptions may play a role in motor neuron degeneration.

"90% of ALS patients do not know the cause of their disease. We are combining two powerful approaches to discover new genetic causes of ALS - the first is to go out into communities to generate data from as many people with ALS as we can find, particularly those who would not be able to come into clinic to participate in research, and the second is to use a method of sequencing that allows us to 'see' as much of the genome as is possible," says Dr. Amy Easton, Ph.D., Senior Director of Scientific Programs at Target ALS.  

Traditional short-read sequencing has helped identify known ALS-associated mutations, but its limited read length makes it difficult to resolve complex regions of the genome where novel variants may lie. Long-read sequencing, like PacBio's HiFi technology, captures DNA fragments ranging from 1,000 to 20,000 base pairs - compared to the 50 to 300 base pairs typical of short-read methods. This allows researchers to more accurately assemble genomes and view the full structure of genes and their regulatory elements. This comprehensive view is essential for ALS, where repeat expansions, cryptic splicing, and regulatory elements may all contribute to disease but often go undetected with short-read tools.

In addition to providing access to longer swaths of DNA and accurate variant calls, HiFi data can be used to generate high-quality transcript isoform information and methylation profiles from each sample allowing researchers to examine how genetic variants may influence RNA expression and epigenetic changes in ALS. This integrated view has the potential to reveal novel disease mechanisms that are invisible to short-read sequencing approaches.

"We're honored to support Target ALS in addressing one of the most urgent challenges in neurodegenerative disease," said David Miller, Vice President of Marketing at PacBio. "ALS has a complex genetic landscape marked by elements that are often missed with traditional sequencing. HiFi sequencing offers the length and accuracy needed to uncover those hidden regions, helping researchers make new connections between genetic variation and disease progression. By making these data broadly available, this project has the potential to accelerate discoveries that could lead to better diagnostics, new therapeutic targets, and ultimately, hope for people living with ALS."

Driving Breakthroughs in ALS Research

Through this collaboration, Target ALS is adding invaluable long-read sequencing data to their Data Engine, which already holds the most comprehensive collection of multi-omic datasets for ALS research. As with all Target ALS resources, access to the Data Engine is open to scientists worldwide at no cost. Whole genomes from this initiative are already available to be mined and analyzed. Together, Target ALS and PacBio continue to enrich this resource, performing short-read, long-read, and RNA sequencing on samples from AGRI, which includes a Global Natural History Study and Community Pop-up Clinics, and Target ALS' Postmortem Tissue Core.

"For most researchers, the expense of long-read sequencing is prohibitive and the ability to obtain human samples is limited. Target ALS sees it as our role to continue to lower the barriers and fill the gaps, enabling rapid discovery of new diagnostic biomarkers and therapeutic targets," says Dr. Manish Raisinghani, M.B.B.S., Ph.D., Chief Executive Officer at Target ALS. 

To start mining the data, visit the Target ALS Data Engine.

About Target ALS

Target ALS is a medical research foundation breaking down barriers to Amyotrophic Lateral Sclerosis (ALS) research to find effective treatments. Since 2013, Target ALS has revolutionized ALS research through its Innovation Ecosystem. By democratizing research through an unbiased review process, providing access to cutting-edge research tools, facilitating cross-disciplinary collaboration, and galvanizing industry involvement, Target ALS accelerates the most promising ideas in scientific research into drug development programs. Driven by impatient optimism, deliberate disruption, and radical collaboration, Target ALS aims to transform ALS into a manageable disease, building a world where Everyone Lives. 

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.

For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements  

This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, advantages, quality or performance of, the benefits or expected benefits of using, PacBio products or technologies, including in connection with Target ALS and its efforts to perform long-read sequencing of genomes from ALS patients; making the ALS genetic data available to scientists world-wide free of charge; intentions to examine how genetic variants includes expression and epigenetic changes in ALS; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results. These risks include, but are not limited to, risks inherent in identifying complicated genetic drivers of disease, including with respect to ALS; developing and commercializing new technologies; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in tariffs, costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; and other risks associated with general macroeconomic conditions and geopolitical instability. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements, including PacBio's preliminary unaudited financial information and PacBio's financial guidance, are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.

Contacts (Target ALS)

Stephanie Ishoo
Manager, Research Communications and Marketing, Target ALS
Stephanie.Ishoo@targetals.org

Contacts (PacBio)

Investors:

Todd Friedman
ir@pacificbiosciences.com

Media:
pr@pacificbiosciences.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/target-als-chooses-pacbio-hifi-sequencing-to-advance-als-research-with-largest-global-genomic-study-to-date-302470691.html

SOURCE Target ALS

FAQ

What is the significance of PacBio's partnership with Target ALS for PACB stock?

The partnership positions PacBio as a leader in neurodegenerative disease research, involving the sequencing of 6,000 genomes and demonstrating the superior capabilities of their HiFi technology for complex genetic analysis.

How does PacBio's HiFi sequencing technology differ from traditional methods?

PacBio's HiFi technology captures DNA fragments of 1,000-20,000 base pairs, compared to traditional short-read methods' 50-300 base pairs, allowing better detection of complex genomic regions and structural variants.

What is the market potential for PACB in the ALS research field?

The partnership to sequence 6,000 genomes represents a significant commercial opportunity, while the global sharing of data through Target ALS Data Engine could drive broader adoption of PacBio's technology in research.

How will the Target ALS partnership impact PacBio's market position?

The partnership establishes PacBio as a key player in neurodegenerative disease research, showcasing their technology's advantages and potentially leading to increased adoption in both research and clinical applications.

What are the expected outcomes of the PACB-Target ALS collaboration?

The collaboration aims to identify new genetic causes of ALS, develop better diagnostics, discover new therapeutic targets, and accelerate breakthroughs in ALS research through comprehensive genetic analysis.